- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06187857
A Virtually Delivered Memory Rehabilitation Protocol in Older Adults (EONMem_OA)
December 28, 2023 updated by: Whitney Allen, Brigham Young University
A Feasibility Study of a Virtually Delivered Ecologically Oriented Neurorehabilitation of Memory (EON-MEM) Protocol in Older Adults
The investigators conducted a feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults.
The primary purposes of this study included determining the feasibility of conducting EON-Mem virtually with older adults and whether a randomized control trial using EON-Mem in older adults is of value.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Twenty-five older adults aged 55 years and older were recruited for participation in the EON-Mem training program adapted and administered virtually.
Measures of emotional functioning and cognitive functioning were administered before and following the intervention.
Participants attended one virtual treatment session per week for a total of six weeks with daily homework assignments.
A priori, feasibility was set at an 80% completion rate.
To address questions regarding feasibility, the investigators calculated descriptive statistics on sample information.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Provo, Utah, United States, 84604
- Brigham Young Unversity
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Individuals 55 and older
Exclusion Criteria:
- Evidence of cognitive dysfunction on the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as evidenced by a score of 3.3 or more
- History of moderate-to-severe TBI
- History of stroke
- Dementia/neurological diagnoses
- Current chemotherapy or radiation
- Current or history of brain cancer
- Poor sensory function including uncorrected vision, hearing, or speaking impairments that could interfere with learning the intervention, including nonnative English speakers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of study protocols.
Time Frame: Through study completion, an average of 8 weeks.
|
To address questions regarding feasibility, the investigators calculated descriptive statistics on sample information and feasibility was set a priori as a completion rate greater than 80% based on previous research.
|
Through study completion, an average of 8 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Memory Outcomes: Repeatable Battery for Neuropsychological Status
Time Frame: Through study completion, an average of 8 weeks.
|
To address secondary outcomes, the investigators calculated reliable change indices for memory outcomes on the Repeatable Battery for Neuropsychological Status.
The reliable change indices vary from less than -1.96 to greater than 1.96.
Greater than 1.96 represents improved memory functioning.
|
Through study completion, an average of 8 weeks.
|
|
Memory Outcomes: Ecological Memory Simulations
Time Frame: Through study completion, an average of 8 weeks.
|
To address secondary outcomes, the investigators calculated reliable change indices for memory outcomes on the Ecological Memory Simulations.
The reliable change indices vary from less than -1.96 to greater than 1.96.
Greater than 1.96 represents improved memory functioning.
|
Through study completion, an average of 8 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2020
Primary Completion (Actual)
December 20, 2021
Study Completion (Actual)
December 20, 2021
Study Registration Dates
First Submitted
November 27, 2023
First Submitted That Met QC Criteria
December 28, 2023
First Posted (Actual)
January 3, 2024
Study Record Updates
Last Update Posted (Actual)
January 3, 2024
Last Update Submitted That Met QC Criteria
December 28, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- EONMem_OA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The investigators will be sharing study procedures, study design, and de-identified participant data on the Open Science Framework (OSF).
IPD Sharing Time Frame
The dataset will be published in January 2024 and will remain on the website.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Study Data/Documents
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurorehabilitation
-
Biruni UniversityCompletedNeurorehabilitation | Clinical Assessment | Physiotherapist | Treatment PreferencesTurkey
-
School of Health Sciences GenevaUniversity Hospital, GenevaRecruitingNeurorehabilitation | Motor Impairment | Theta Burst Stimulation | Chronic Stroke PatientSwitzerland
-
Kocaeli Sağlık ve Teknoloji ÜniversitesiCompletedPhysical Therapy | Virtual Reality | Education | NeurorehabilitationTurkey (Türkiye)
-
University of RzeszowDonum Corde Rehabilitation CenterNot yet recruitingNervous System Diseases | Physical Activity | Neurorehabilitation | Biomedical Enhancement
-
University of California, Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMovement Disorders | Neurorehabilitation | Non-invasive Activity RecordingUnited States
-
Olivier LambercyCereneo AGEnrolling by invitationStroke Rehabilitation | NeurorehabilitationSwitzerland
-
University of AarhusTerminatedStroke | NeurorehabilitationDenmark
-
University of LiegeUniversity Hospital Sart Tilman, LiegeNot yet recruitingMultiple Sclerosis | Rehabilitation | Neuro-Degenerative Disease | NeurorehabilitationBelgium
-
BioRobotics Group - Spanish National Research Council...Castilla-La Mancha Health Service; Hospital Nacional de Parapléjicos de Toledo and other collaboratorsCompletedSpinal Cord Injury | Neurorehabilitation | Spinal Cord Injuries (SCI) | Robot Assisted Gait TrainingSpain
-
Charles University, Czech RepublicMinistry of Health, Czech RepublicNot yet recruitingMultiple Sclerosis | Rehabilitation | Neurorehabilitation | Rehabilitation ExerciseCzechia
Clinical Trials on Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterBristol-Myers Squibb; National Cancer Institute (NCI); Gateway for Cancer ResearchActive, not recruitingRecurrent Glioblastoma | Refractory GlioblastomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)SuspendedRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic LeukemiaUnited States